252 related articles for article (PubMed ID: 34271309)
21. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity.
Khunger A; Battel L; Wadhawan A; More A; Kapoor A; Agrawal N
Curr Oncol Rep; 2020 Jun; 22(7):65. PubMed ID: 32514647
[TBL] [Abstract][Full Text] [Related]
22. Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study.
Delombaerde D; De Sutter J; Croes L; Vervloet D; Moerman V; Van de Veire N; Willems AM; Wouters K; Peeters M; Prenen H; Vulsteke C
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111382
[TBL] [Abstract][Full Text] [Related]
23. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G
Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis.
Puzanov I; Subramanian P; Yatsynovich YV; Jacobs DM; Chilbert MR; Sharma UC; Ito F; Feuerstein SG; Stefanovic F; Switzer B; Hicar MD; Curtis AB; Spangenthal EJ; Dy GK; Ernstoff MS; Vachhani P; Page BJ; Agrawal N; Khunger A; Kapoor A; Hattoum A; Schentag JJ
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34162715
[TBL] [Abstract][Full Text] [Related]
25. Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors.
Furukawa A; Tamura Y; Taniguchi H; Kawamura A; Nagase S; Hayashi A; Tada Y; Sase K; Hatake K
J Cardiol; 2023 Jan; 81(1):63-67. PubMed ID: 35953399
[TBL] [Abstract][Full Text] [Related]
26. A case study of myopericarditis due to immune checkpoint inhibitor therapy: Proposed surveillance and management.
Kuhnly NM; Coviello JS
J Am Assoc Nurse Pract; 2023 May; 35(5):317-321. PubMed ID: 37000118
[TBL] [Abstract][Full Text] [Related]
27. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
Agostinetto E; Eiger D; Lambertini M; Ceppi M; Bruzzone M; Pondé N; Plummer C; Awada AH; Santoro A; Piccart-Gebhart M; de Azambuja E
Eur J Cancer; 2021 May; 148():76-91. PubMed ID: 33740500
[TBL] [Abstract][Full Text] [Related]
28. Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience.
Xiao J; Li X; Wang X; Guan Y; Liu H; Liang J; Li Y; Wang B; Wang J
Front Cardiovasc Med; 2023; 10():1093383. PubMed ID: 37089888
[TBL] [Abstract][Full Text] [Related]
29. [Call for attention to the scientific issues in cardiovascular adverse effects associated with immune checkpoint inhibitors].
Zhang ZR
Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(42):3328-3331. PubMed ID: 37963733
[TBL] [Abstract][Full Text] [Related]
30. [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].
Liu Y; Chen Y; Zeng Z; Liu A
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):668-672. PubMed ID: 34521189
[TBL] [Abstract][Full Text] [Related]
31. Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study.
Ulndreaj A; Brinc D; Altan M; Pons-Belda OD; Fernandez-Uriarte A; Mu-Mosley H; Fattah F; von Itzstein MS; Soosaipillai A; Kulasingam V; Palaskas NL; Gerber DE; Diamandis EP; Heymach JV; Prassas I
Clin Chem Lab Med; 2023 Jan; 61(1):154-161. PubMed ID: 36287134
[TBL] [Abstract][Full Text] [Related]
32. Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
Sarocchi M; Grossi F; Arboscello E; Bellodi A; Genova C; Dal Bello MG; Rijavec E; Barletta G; Rossi G; Biello F; Ghigliotti G; Canepa M; Mussap M; Brunelli C; Spallarossa P
Oncologist; 2018 Aug; 23(8):936-942. PubMed ID: 29567824
[TBL] [Abstract][Full Text] [Related]
33. Prospective cardiovascular events in patients with advanced thoracic cancer treated with immune checkpoint inhibitor.
Toublanc AC; Faure M; Verdy G; Rabeau A; Houard V; Veillon R; Bardel C; Vergnenegre C; Dos Santos P; Mazieres J; Zysman M
Eur J Cancer; 2024 Jun; 207():114191. PubMed ID: 38936104
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular immune-related adverse events: Evaluation, diagnosis and management.
Liu Y; Wu W
Asia Pac J Clin Oncol; 2020 Aug; 16(4):232-240. PubMed ID: 32129935
[TBL] [Abstract][Full Text] [Related]
35. Teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: a case report.
Ye Y; Li Y; Zhang S; Han G
J Int Med Res; 2022 Oct; 50(10):3000605221133259. PubMed ID: 36300305
[TBL] [Abstract][Full Text] [Related]
36. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
[No Abstract] [Full Text] [Related]
37. Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects.
Paluri RK; Pulipati Y; Regalla DKR
Oncol Rev; 2023; 17():11456. PubMed ID: 38045806
[TBL] [Abstract][Full Text] [Related]
38. Cardiotoxicities associated with immune checkpoint inhibitors.
Yang S; Asnani A
Curr Probl Cancer; 2018 Jul; 42(4):422-432. PubMed ID: 30173878
[TBL] [Abstract][Full Text] [Related]
39. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.
Frayberg M; Yung A; Zubiri L; Zlotoff DA; Reynolds KL
Curr Treat Options Oncol; 2021 May; 22(6):53. PubMed ID: 34037918
[TBL] [Abstract][Full Text] [Related]
40. A Systematic Review of Myocarditis Induced by Immune Checkpoint Inhibitors: How Concerning Is the Most Common Cardiotoxicity of Immune Checkpoint Inhibitors?
Moradi A; Kodali A; Okoye C; Klein DH; Mohamoud I; Olanisa OO; Parab P; Chaudhary P; Mukhtar S; Mohammed L
Cureus; 2023 Jul; 15(7):e42071. PubMed ID: 37602125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
